Cogent Biosciences, Inc. (COGT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 59.30M USD | Liabilities, Current |
| Cash and equivalents | 181.17M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 611.13M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $59.30M | $181.17M | $611.13M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $57.98M | $241.21M | $625.17M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $63.95M | $312.01M | $588.75M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $62.25M | $125.30M | $265.59M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $58.42M | $127.60M | $110.25M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $49.32M | $126.00M | $119.66M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $55.71M | $98.17M | $188.91M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $53.05M | $97.05M | $238.47M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $40.00M | $88.22M | $275.00M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $36.69M | $215.80M | $219.94M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $38.17M | $53.23M | $212.48M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $34.72M | $86.81M | $192.23M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $25.76M | $214.32M | $115.08M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $21.12M | $160.70M | $59.57M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $26.85M | $139.89M | $119.39M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $23.55M | $140.57M | $148.53M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $27.66M | $325.56M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $17.88M | $191.05M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $17.08M | $219.68M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $16.71M | $202.89M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $13.68M | $218.10M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $8.24M | $230.74M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $13.09M | $242.19M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $20.12M | $129.42M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $8.27M | $21.34M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $9.25M | $29.60M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $13.25M | $37.42M | (m) | $2.00M | (m) | (m) |
| 2019-09-30 | $46.76M | $24.43M | $45.88M | $0.00 | $880.00K | (m) | 1.91× |
| 2019-06-30 | $57.35M | $24.31M | $55.86M | $0.00 | $1.49M | (m) | 2.36× |
| 2019-03-31 | $69.14M | $26.34M | $59.11M | $7.99M | $2.04M | (m) | 2.62× |
| 2018-12-31 | $80.26M | $24.95M | $55.67M | $22.92M | $1.67M | (m) | 3.22× |
| 2018-09-30 | $88.54M | $26.38M | $49.30M | $37.82M | $1.42M | (m) | 3.36× |
| 2018-06-30 | $95.65M | $24.81M | $46.73M | $47.72M | $1.20M | (m) | 3.85× |
| 2018-03-31 | $34.00M | $22.96M | $25.70M | $6.70M | $1.60M | (m) | 1.48× |
| 2017-12-31 | $41.79M | $11.19M | $28.27M | $12.69M | $830.00K | (m) | 3.73× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |